Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial

American Journal of Transplantation

Volumn 8, Issue 7, 2008, Pages 1480-1485

  Margreiter, R ^a   Klempnauer, J ^b   Neuhaus, P ^c   Muehlbacher, F ^d   Boesmueller, C ^a   Calne, R Y ^e  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alemtuzumab; Kidney transplantation; Tacrolimus monotherapy

Indexed keywords

ALEMTUZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TREATMENT OUTCOME;

EID: 47249142845     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02273.x     Document Type: Article

References (15)

1. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007 7: 586 594.
2. Monaco AP, Morris PJ. Clinical tolerance: The end of the beginning. Transplantation 2004 77: 921 925.
3. Kean LS, Gangappa S, Pearson TC, Larsen CP. Transplant tolerance in non-human primates: Progress, current challenges and unmet needs. Am J Transplant 2006 6: 884 893.
4. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005 80: 1051 1059.
5. Kirk AD, Hale DA, Mannon RB, Kleinert DE, Hoffmann SC, Kampen RL. Results from a Human Renal Allograft Tolerance Trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 2003 76 (1 120 129.
6. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998 351: 1701 1702.
7. Calne R, Moffatt SD, Friend PJ et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999 88: 1613 1616.
8. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody mediated T-cell depletion. Am J Transplant 2005 5: 465 474.
9. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55: 713 723.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16: 31 41.
11. Vathsala A, Ona ET, Tan S-Y et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005 80: 765 774.
12. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357: 2562 2575.
13. Tan HP, Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006 6: 2409 2417.
14. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999 354: 1691.
15. Watson CJE, Bradley JA, Friend PJ et al. Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005 5: 1347 1353.